Baxter International (BAX)
(Delayed Data from NYSE)
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.54 USD
+1.05 (2.88%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $37.40 -0.14 (-0.37%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth C Momentum C VGM
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe
by Zacks Equity Research
With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.
What's in the Cards for HealthEquity (HQY) in Q2 Earnings?
by Zacks Equity Research
Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.
Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.
Quest Diagnostics' New Acquisitions and Pacts Aid Growth
by Zacks Equity Research
Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.
Patterson Companies (PDCO) Earnings Beat Estimates in Q1
by Zacks Equity Research
Patterson Companies' (PDCO) Q1 results benefit from higher revenues, gross margin expansion, solid show by Corporate segment and lower expenses.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Varian's ProBeam Compact System Picked by University of Miami
by Zacks Equity Research
Varian (VAR) sees notable developments in its Proton Solutions business of late.
Henry Schein Expands SolutionsHub With CueSquared MobilePay
by Zacks Equity Research
The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.
Ecolab (ECL) Expands Product Portfolio With New Technology
by Zacks Equity Research
Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors' confidence continues to be high on ResMed's (RMD) prospects.
Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.
Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.
Haemonetics Rides on Strong Plasma and Global Expansion
by Zacks Equity Research
Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).
Here's Why You Should Add Abbott (ABT) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) on its balanced segmental performances.
Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results
by Zacks Equity Research
This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.
Medtronic (MDT) Benefits from Strength Across Business Groups
by Zacks Equity Research
Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
by Zacks Equity Research
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
Here's Why You Should Hold on to Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
Here's Why You Should Invest in NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investor confidence is currently high on NuVasive's (NUVA) prospects.
What's in Store for Cooper Companies (COO) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at CVI and CSI and higher revenues are likely to aid Cooper Companies (COO) in Q3 earnings.
Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining from several positive developments of late.
Why Is Baxter (BAX) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision's Store Launches on Track Despite Cost Woes
by Zacks Equity Research
National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.
Veeva (VEEV) Introduces MuleSoft Connector for Vault Platform
by Zacks Equity Research
Veeva's (VEEV) Vault platform sees a slew of developments in recent times.
Edwards Lifesciences Sapien 3 System Recall Classified Class I
by Zacks Equity Research
Edwards Lifesciences (EW) initiated the Field Corrective Action after receiving reports of 17 injuries and a death from the use of the Sapien 3 Ultra delivery system.